Certified by Founder
Lodge
Ensoma
start up
United States
- Boston, MA
- 06/02/2023
- Series B
- $85,000,000
At Ensoma, we develop one-time in vivo treatments that precisely engineer any or all blood and immune cells to cure diseases from within.
- Industry Biotechnology Research
- Website https://ensoma.com/
- LinkedIn https://www.linkedin.com/company/ensomabio/people/?keywords=founder
SpeedLabs | $6,500,000 | (Jun 2, 2026)
Invertix | $1,977,831 | (Jun 2, 2026)
XCENA | $135,000,000 | (Jun 2, 2026)
Gray Swan | $40,000,000 | (Jun 2, 2026)
Human Archive (YC W26) | $8,200,000 | (Jun 2, 2026)
Countable Labs | $26,000,000 | (May 29, 2026)
Rep AI | $6,200,000 | (May 29, 2026)
Psilera | $8,800,000 | (May 29, 2026)
Reactor | $59,000,000 | (May 29, 2026)
MokN | $15,000,000 | (May 29, 2026)
Crimson | $2,500,000 | (May 29, 2026)
Orebella | Undisclosed Amount | (May 29, 2026)